Utilizing Pharmacogenomics to Reduce Adverse Drug Events

Amin, Nishita Shah

doi:10.34297/ajbsr.2020.11.001638

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Approximately 20% to 30% of ADRs can be predicted by this testing. 15 It is useful for identifying genetic variants that encode certain cytochrome P450 enzymes (e.g., cytochrome P450 2C9 [CYP2C9], CYP3As, CYP2D6, CYP2C19). 15 These enzymes play critical roles in the metabolism and clearance of most drugs used in clinical settings.…”

Section: Adrs and Pharmacogenomicsmentioning

confidence: 99%

“…15 It is useful for identifying genetic variants that encode certain cytochrome P450 enzymes (e.g., cytochrome P450 2C9 [CYP2C9], CYP3As, CYP2D6, CYP2C19). 15 These enzymes play critical roles in the metabolism and clearance of most drugs used in clinical settings. 16 For example, CYP2D6 participates in the metabolism of approximately 20% of drugs.…”

Section: Adrs and Pharmacogenomicsmentioning

confidence: 99%

Section: Adrs and Pharmacogenomicsmentioning

confidence: 99%

See 2 more Smart Citations

Structure–activity relationships and interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm

Thabet,

Alshar,

Alabdallah

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Adverse drug reactions represent a major health burden because they cause notable patient morbidity and mortality. From this viewpoint, several strategies have been developed to prevent or reduce adverse drug reactions. One such strategy is the use of pharmacogenomics. Interindividual variability in drug response and adverse effects is mainly attributable to genetic variation in enzymes such as sulfotransferases and cytochrome P450s. The current narrative review discusses the relationship between the structure and activity of drugs. Specifically, the activity of drugs can be increased and/or their adverse effects can be reduced by altering specific positions in their structures.

show abstract

Section: Adrs and Pharmacogenomicsmentioning

confidence: 99%

Section: Adrs and Pharmacogenomicsmentioning

confidence: 99%

See 1 more Smart Citation

Structure–activity relationships and interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm

Thabet,

Alshar,

Alabdallah

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

show abstract

Effectiveness of pharmacogenomics educational interventions on healthcare professionals and health professions students: A systematic review

Omran,

Leong,

Blebil

et al. 2023

Research in Social and Administrative Pharmacy

View full text Add to dashboard Cite

The needs and gaps in pharmacogenomics knowledge and education among healthcare professionals in Malaysia: A multisite Delphi study

Omran,

Leong,

Blebil

et al. 2024

Clinical Translational Sci

View full text Add to dashboard Cite

Lack of pharmacogenomics knowledge among healthcare professionals is the most significant cited barrier to implementing pharmacogenomics in clinical settings. Despite the growth in research initiatives and awareness of pharmacogenomics, healthcare professionals continue to report a lack of knowledge and confidence in practicing pharmacogenomics. This study aims to assess the current pharmacogenomics knowledge gaps and learning needs of healthcare professionals in Malaysia. A modified Delphi with a multidisciplinary expert panel was conducted, and a purposive sampling method was used with predefined selection criteria. Fourteen study sites in Malaysia were included. The cut‐off value to approach consensus was predefined as a threshold of 60% or higher, and a quantitative descriptive statistical analysis was performed. The study demonstrated that all experts rated the suggested educational content components as essential/important to be included in the educational intervention. Additionally, experts highlighted the significant barriers and gaps to adopting and practicing pharmacogenomics. To conclude, this multisite Delphi study enabled the development of a tailored, effective, evidence‐based, competency‐based educational intervention in pharmacogenomics for healthcare professionals in Malaysia. To keep up with the rapid evolution of the pharmacogenomics field, healthcare professionals should be equipped with the necessary competencies required to practice pharmacogenomics for better health outcomes. Future research is needed to determine the feasibility of the proposed educational intervention.

show abstract

Utilizing Pharmacogenomics to Reduce Adverse Drug Events

Abstract: This work is licensed under Creative Commons Attribution 4.0 License AJBSR.MS.ID.001638.

Cited by 3 publications

References 29 publications

Structure–activity relationships and interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm

Structure–activity relationships and interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm

Effectiveness of pharmacogenomics educational interventions on healthcare professionals and health professions students: A systematic review

The needs and gaps in pharmacogenomics knowledge and education among healthcare professionals in Malaysia: A multisite Delphi study

Contact Info

Product

Resources

About